macmillan cancer support
macmillan cancer support Company Information
Company Number
02400969
Website
http://macmillan.org.ukRegistered Address
89 albert embankment, london, SE1 7UQ
Industry
Medical nursing home activities
Telephone
02078407840
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
-0%
macmillan cancer support Estimated Valuation
Pomanda estimates the enterprise value of MACMILLAN CANCER SUPPORT at £268.6m based on a Turnover of £227.1m and 1.18x industry multiple (adjusted for size and gross margin).
macmillan cancer support Estimated Valuation
Pomanda estimates the enterprise value of MACMILLAN CANCER SUPPORT at £0 based on an EBITDA of £-24.4m and a 9.26x industry multiple (adjusted for size and gross margin).
macmillan cancer support Estimated Valuation
Pomanda estimates the enterprise value of MACMILLAN CANCER SUPPORT at £141.6m based on Net Assets of £48.3m and 2.93x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Macmillan Cancer Support AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Macmillan Cancer Support Overview
Macmillan Cancer Support is a live company located in london, SE1 7UQ with a Companies House number of 02400969. It operates in the medical nursing home activities sector, SIC Code 86102. Founded in June 1989, it's largest shareholder is unknown. Macmillan Cancer Support is a mature, mega sized company, Pomanda has estimated its turnover at £227.1m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Macmillan Cancer Support Health Check
Pomanda's financial health check has awarded Macmillan Cancer Support a 3 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 6 areas for improvement. Company Health Check FAQs
4 Strong
1 Regular
6 Weak
Size
annual sales of £227.1m, make it larger than the average company (£4.2m)
£227.1m - Macmillan Cancer Support
£4.2m - Industry AVG
Growth
3 year (CAGR) sales growth of -1%, show it is growing at a slower rate (4.1%)
-1% - Macmillan Cancer Support
4.1% - Industry AVG
Production
with a gross margin of 32.6%, this company has a comparable cost of product (32.6%)
32.6% - Macmillan Cancer Support
32.6% - Industry AVG
Profitability
an operating margin of -10.9% make it less profitable than the average company (12.3%)
-10.9% - Macmillan Cancer Support
12.3% - Industry AVG
Employees
with 1687 employees, this is above the industry average (106)
1687 - Macmillan Cancer Support
106 - Industry AVG
Pay Structure
on an average salary of £53.1k, the company has a higher pay structure (£23.1k)
£53.1k - Macmillan Cancer Support
£23.1k - Industry AVG
Efficiency
resulting in sales per employee of £134.6k, this is more efficient (£40.8k)
£134.6k - Macmillan Cancer Support
£40.8k - Industry AVG
Debtor Days
it gets paid by customers after 0 days, this is earlier than average (20 days)
0 days - Macmillan Cancer Support
20 days - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Macmillan Cancer Support
- - Industry AVG
Stock Days
it holds stock equivalent to 0 days, this is more than average (0 days)
0 days - Macmillan Cancer Support
0 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 4 weeks, this is less cash available to meet short term requirements (28 weeks)
4 weeks - Macmillan Cancer Support
28 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 79.7%, this is a higher level of debt than the average (57.9%)
79.7% - Macmillan Cancer Support
57.9% - Industry AVG
macmillan cancer support Credit Report and Business Information
Macmillan Cancer Support Competitor Analysis
Perform a competitor analysis for macmillan cancer support by selecting its closest rivals and benchmarking them against 12 key performance metrics.
macmillan cancer support Ownership
MACMILLAN CANCER SUPPORT group structure
Macmillan Cancer Support has 7 subsidiary companies.
Ultimate parent company
MACMILLAN CANCER SUPPORT
02400969
7 subsidiaries
macmillan cancer support directors
Macmillan Cancer Support currently has 12 directors. The longest serving directors include Mr Iain Cornish (Jan 2017) and Dr Jagjit Ahluwalia (Apr 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Iain Cornish | 63 years | Jan 2017 | - | Director | |
| Dr Jagjit Ahluwalia | England | 62 years | Apr 2017 | - | Director |
| Mr Richard Murley | 67 years | Apr 2017 | - | Director | |
| Mr Mohammed Mehmet | 64 years | Oct 2019 | - | Director | |
| Mrs Catherine Howe | United Kingdom | 56 years | Oct 2019 | - | Director |
| Mr Mohammed Mehmet | England | 63 years | Oct 2019 | - | Director |
| Mr Mark Ware | 65 years | Oct 2019 | - | Director | |
| Mr Nicholas Owen | United Kingdom | 60 years | Sep 2020 | - | Director |
| Ms Rachel Higham | 50 years | Sep 2020 | - | Director | |
| Prof Jean Abraham | England | 56 years | Jun 2021 | - | Director |
MACMILLAN CANCER SUPPORT financials
Macmillan Cancer Support's latest turnover from December 2022 is £227.1 million and the company has net assets of £48.3 million. According to their latest financial statements, Macmillan Cancer Support has 1,687 employees and maintains cash reserves of £8.2 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 227,145,000 | 230,707,000 | 194,889,000 | 232,833,000 | 235,718,000 | 252,692,000 | 247,441,000 | 230,211,000 | 218,562,000 | 189,709,000 | 155,688,000 | 144,530,000 | 133,605,000 | 123,394,000 |
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | ||||||||||||||
| Gross Profit | ||||||||||||||
| Admin Expenses | ||||||||||||||
| Operating Profit | ||||||||||||||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-Tax Profit | -24,515,000 | -3,348,000 | 47,086,000 | -12,906,000 | -25,034,000 | -3,730,000 | 1,850,000 | -10,280,000 | -3,125,000 | 8,635,000 | -7,634,000 | -8,261,000 | 2,256,000 | 7,109,000 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -24,515,000 | -3,348,000 | 47,086,000 | -12,906,000 | -25,034,000 | -3,730,000 | 1,850,000 | -10,280,000 | -3,125,000 | 8,635,000 | -7,634,000 | -8,261,000 | 2,256,000 | 7,109,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | -24,515,000 | -3,348,000 | 47,086,000 | -12,906,000 | -25,034,000 | -3,730,000 | 1,850,000 | -10,280,000 | -3,125,000 | 8,635,000 | -7,634,000 | -8,261,000 | 2,256,000 | 7,109,000 |
| Employee Costs | 89,534,000 | 75,500,000 | 89,145,000 | 89,798,000 | 87,410,000 | 76,944,000 | 71,490,000 | 67,489,000 | 58,695,000 | 50,489,000 | 44,811,000 | 39,497,000 | 34,038,000 | 31,909,000 |
| Number Of Employees | 1,687 | 1,527 | 1,754 | 1,810 | 1,801 | 1,715 | 1,642 | 1,570 | 1,384 | 1,228 | 1,112 | 999 | 875 | 814 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 6,709,000 | 7,148,000 | 7,633,000 | 7,679,000 | 7,531,000 | 7,944,000 | 7,664,000 | 5,612,000 | 2,590,000 | 2,111,000 | 2,819,000 | 2,772,000 | 2,931,000 | 2,841,000 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 99,288,000 | 101,126,000 | 101,695,000 | 133,893,000 | 119,359,000 | 164,941,000 | 155,887,000 | 112,040,000 | 110,670,000 | 45,688,000 | 79,074,000 | 36,245,000 | 73,482,000 | 30,605,000 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 105,997,000 | 108,274,000 | 109,328,000 | 141,572,000 | 126,890,000 | 172,885,000 | 163,551,000 | 117,652,000 | 113,260,000 | 47,799,000 | 81,893,000 | 39,017,000 | 76,413,000 | 33,446,000 |
| Stock & work in progress | 327,000 | 370,000 | 311,000 | 1,158,000 | 84,000 | 68,000 | 58,000 | 1,244,000 | 871,000 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 617,000 | 519,000 | 608,000 | 570,000 | 61,561,000 | 2,201,000 | 741,000 | 690,000 | 461,000 | 130,000 | 270,000 | 1,322,000 | 22,379,000 | 21,474,000 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 86,747,000 | 78,110,000 | 66,366,000 | 65,988,000 | 9,027,000 | 63,770,000 | 62,577,000 | 52,573,000 | 44,112,000 | 47,160,000 | 33,190,000 | 28,228,000 | 6,332,000 | 5,466,000 |
| Cash | 8,238,000 | 10,423,000 | 11,384,000 | 6,564,000 | 6,719,000 | 5,395,000 | 3,386,000 | 4,905,000 | 7,061,000 | 4,878,000 | 3,403,000 | 6,681,000 | 7,699,000 | 8,258,000 |
| misc current assets | 35,366,000 | 45,905,000 | 28,355,000 | 39,337,000 | 54,817,000 | 39,453,000 | 35,389,000 | 75,004,000 | 73,961,000 | 111,660,000 | 71,162,000 | 113,462,000 | 79,709,000 | 114,756,000 |
| total current assets | 131,295,000 | 135,327,000 | 107,024,000 | 113,617,000 | 132,208,000 | 110,887,000 | 102,151,000 | 134,416,000 | 126,466,000 | 163,828,000 | 108,025,000 | 149,693,000 | 116,119,000 | 149,954,000 |
| total assets | 237,292,000 | 243,601,000 | 216,352,000 | 255,189,000 | 259,098,000 | 283,772,000 | 265,702,000 | 252,068,000 | 239,726,000 | 211,627,000 | 189,918,000 | 188,710,000 | 192,532,000 | 183,400,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 3,566,000 | 5,172,000 | 7,283,000 | 6,460,000 | 5,926,000 | 9,514,000 | 0 | 6,015,000 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 52,238,000 | 46,369,000 | 44,757,000 | 41,866,000 | 38,654,000 | 36,333,000 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 97,778,000 | 85,422,000 | 65,720,000 | 76,120,000 | 76,205,000 | 78,060,000 | 69,560,000 | 68,729,000 | 15,725,000 | 4,516,000 | 9,270,000 | 6,947,000 | 6,452,000 | 5,845,000 |
| total current liabilities | 97,778,000 | 85,422,000 | 69,286,000 | 81,292,000 | 83,488,000 | 84,520,000 | 75,486,000 | 78,243,000 | 67,963,000 | 56,900,000 | 54,027,000 | 48,813,000 | 45,106,000 | 42,178,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 103,648,000 | 87,317,000 | 81,412,000 | 79,979,000 | 76,721,000 | 70,876,000 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 89,677,000 | 82,856,000 | 68,733,000 | 136,920,000 | 140,347,000 | 133,199,000 | 125,429,000 | 115,293,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 1,572,000 | 1,205,000 | 725,000 | 734,000 | 533,000 | 467,000 | 485,000 | 472,000 | 573,000 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 91,249,000 | 84,061,000 | 69,458,000 | 137,654,000 | 140,880,000 | 133,666,000 | 125,914,000 | 115,765,000 | 104,221,000 | 87,317,000 | 81,412,000 | 79,979,000 | 76,721,000 | 71,162,000 |
| total liabilities | 189,027,000 | 169,483,000 | 138,744,000 | 218,946,000 | 224,368,000 | 218,186,000 | 201,400,000 | 194,008,000 | 172,184,000 | 144,217,000 | 135,439,000 | 128,792,000 | 121,827,000 | 113,340,000 |
| net assets | 48,265,000 | 74,118,000 | 77,608,000 | 36,243,000 | 34,730,000 | 65,586,000 | 64,302,000 | 58,060,000 | 67,542,000 | 67,410,000 | 54,479,000 | 59,918,000 | 70,705,000 | 70,060,000 |
| total shareholders funds | 48,265,000 | 74,118,000 | 77,608,000 | 36,243,000 | 34,730,000 | 65,586,000 | 64,302,000 | 58,060,000 | 67,542,000 | 67,410,000 | 54,479,000 | 59,918,000 | 70,705,000 | 70,060,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | ||||||||||||||
| Depreciation | 417,000 | 485,000 | 510,000 | 428,000 | 769,000 | 451,000 | 482,000 | 502,000 | 618,000 | 867,000 | 1,051,000 | 948,000 | 899,000 | 774,000 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock | -43,000 | 59,000 | -847,000 | 1,074,000 | 16,000 | 10,000 | -1,186,000 | 373,000 | 871,000 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 8,735,000 | 11,655,000 | 416,000 | -4,030,000 | 4,617,000 | 2,653,000 | 10,055,000 | 8,690,000 | -2,717,000 | 13,830,000 | 3,910,000 | 839,000 | 1,771,000 | 26,940,000 |
| Creditors | 0 | -3,566,000 | -1,606,000 | -2,111,000 | 823,000 | 534,000 | -3,588,000 | 9,514,000 | -6,015,000 | 6,015,000 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 12,356,000 | 19,702,000 | -10,400,000 | -85,000 | -1,855,000 | 8,500,000 | 831,000 | 53,004,000 | 11,209,000 | -4,754,000 | 2,323,000 | 495,000 | 607,000 | 5,845,000 |
| Deferred Taxes & Provisions | 367,000 | 480,000 | -9,000 | 201,000 | 66,000 | -18,000 | 13,000 | -101,000 | 573,000 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | ||||||||||||||
| Investing Activities | ||||||||||||||
| capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -157,000 | -40,981,000 | 3,757,000 | -66,680,000 | 13,646,000 |
| Change in Investments | -1,838,000 | -569,000 | -32,198,000 | 14,534,000 | -45,582,000 | 9,054,000 | 43,847,000 | 1,370,000 | 64,982,000 | -33,386,000 | 42,829,000 | -37,237,000 | 42,877,000 | 30,605,000 |
| cash flow from investments | 1,838,000 | 569,000 | 32,198,000 | -14,534,000 | 45,582,000 | -9,054,000 | -43,847,000 | -1,370,000 | -64,982,000 | 33,229,000 | -83,810,000 | 40,994,000 | -109,557,000 | -16,959,000 |
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -52,238,000 | 5,869,000 | 1,612,000 | 2,891,000 | 3,212,000 | 2,321,000 | 36,333,000 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -103,648,000 | 16,331,000 | 5,905,000 | 1,433,000 | 3,258,000 | 5,845,000 | 70,876,000 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 6,821,000 | 14,123,000 | -68,187,000 | -3,427,000 | 7,148,000 | 7,770,000 | 10,136,000 | 115,293,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from financing | 5,483,000 | 13,981,000 | -73,908,000 | 10,992,000 | 1,326,000 | 12,784,000 | 14,528,000 | -39,795,000 | 25,457,000 | 11,813,000 | 6,519,000 | 3,944,000 | 6,555,000 | 170,160,000 |
| cash and cash equivalents | ||||||||||||||
| cash | -2,185,000 | -961,000 | 4,820,000 | -155,000 | 1,324,000 | 2,009,000 | -1,519,000 | -2,156,000 | 2,183,000 | 1,475,000 | -3,278,000 | -1,018,000 | -559,000 | 8,258,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -2,185,000 | -961,000 | 4,820,000 | -155,000 | 1,324,000 | 2,009,000 | -1,519,000 | -2,156,000 | 2,183,000 | 1,475,000 | -3,278,000 | -1,018,000 | -559,000 | 8,258,000 |
P&L
December 2022turnover
227.1m
-2%
operating profit
-24.8m
0%
gross margin
32.7%
-0.98%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
48.3m
-0.35%
total assets
237.3m
-0.03%
cash
8.2m
-0.21%
net assets
Total assets minus all liabilities
macmillan cancer support company details
company number
02400969
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
86102 - Medical nursing home activities
incorporation date
June 1989
age
35
accounts
Group
ultimate parent company
previous names
macmillan cancer support (October 2009)
macmillan cancer relief (June 2006)
incorporated
UK
address
89 albert embankment, london, SE1 7UQ
last accounts submitted
December 2022
macmillan cancer support Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to macmillan cancer support.
macmillan cancer support Companies House Filings - See Documents
| date | description | view/download |
|---|
